Abstract
Drug repositioning is regarded as the pharma industry' s solution to falling
R&D productivity and weakening product pipelines, successful repositioned
drugs such as raloxifene ( Evista; Lilly), thalidomide (Thalomid; Celegene),
(Exubera; Pfizer/Nektar)have enabled innovative companies to adopt lower risk
strategies to optimize product pipelines. Drug Repositioning Strategies is a
new report that provides in-depth analysis of leading pharma companies that
are using novel technologies to reposition failed, marketed or reformulated
compounds. This report analyzes strategies that are currently being employed
by the leading players and the associated opportunities and challenges arising
from them, enabling you to understand trends in the market and optimize your
R&D pipeline. Use this report to examine current approaches to drug
repositioning and identify successful technologies and business models that
can help your organization deliver enhanced clinical and commercial output.
View Cart
